Abstract: This invention features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof, including cholesterol, folate, galactose, galactosamine, N-acetyl galactosamine, PEG, phospholipid, peptide and human serum albumin (HSA) derived conjugates of biologically active compounds, including antibodies, antivirals, chemotherapeutics, peptides, proteins, hormones, nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids, DNAzymes, allozymes, antisense, dsRNA, siNA, siRNA, triplex oligonucleotides, 2,5-A chimeras, decoys and aptamers.

Abstract: The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, short interfering RNA (siRNA), short interfering nuleic acid (siNA), and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 (VEGFR1) and/or KDR (VEGFR2). Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and other conditions associated with VEGF-R are provided, optionally in conjunction with other therapeutic agents such as interferons.

Abstract: The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 and KDR. Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and ocular diseases are provided, optionally in conjunction with other therapeutic agents.

Abstract: The present invention relates to an enzymatic RNA molecule which cleaves mRNA derived from c-myc gene.

Abstract: The present invention relates to nucleic acid molecules which block synthesis and/or expression of an mRNA encoding B7-1, B7-2, B7-3 and/or CD40.

Abstract: The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, and antisense, which modulate the expression of NOGO and NOGO receptor genes.

Abstract: Process for chemical synthesis of methoxy nucleosides.

Abstract: An enzymatic RNA molecule which specifically cleaves mRNA encoded by an mdr-1 gene.

Abstract: The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, allozymes and antisense, which modulate the expression of epidermal growth factor receptor genes.

Abstract: Nucleic acid catalysts, method of screening for variants of nucleic acid catalysts, synthesis of ribozyme libraries and discovery of gene sequences are described.

Abstract: Enzymatic nucleic acid molecule containing one or more non-nucleotide mimetics, and having activity to cleave an RNA or DNA molecule.

Abstract: A compound having the formula: 1

Abstract: Method to produce a more active ribozyme by introducing a modified base into a substrate binding arm of the ribozyme or its catalytic core.

Abstract: The present invention relates to an enzymatic RNA molecule which cleaves mRNA derived from c-myc gene.

Abstract: The present invention concerns methods and reagents useful in modulating prostaglandin D2 receptor (PTGDR) and/or prostaglandin D2 synthetase (PTGDS) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against PTGDR and/or PTGDS.

Abstract: A nucleic acid catalyst comprising at least one L-nucleotide substitution.

Abstract: Novel xylo nucleoside or xylo nucleotide analogs, polynucleotides comprising xylo nucleotide substitution, processes for their synthesis and incorporation into polynucleotides.

Abstract: An enzymatic nucleic acid molecule comprising a 5′- and/or a 3′-cap structure, wherein said structure is not a 5′-5′-linked inverted nucleotide or a 3′-3′-linked inverted nucleotide.

Abstract: The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor.

Abstract: Nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, allozymes (allosteric ribozymes, aptazymes) and antisense, which modulate and/or detect the expression of molecular targets impacting the development and progression of Alzheimer's disease, in particular, the expression of beta secretase (BACE), presenilin-2 (ps-2), and amyloid precursor protein (APP) genes.